CO6362021A2 - Composiciones y metodos de uso para variantes de trombomodulina - Google Patents

Composiciones y metodos de uso para variantes de trombomodulina

Info

Publication number
CO6362021A2
CO6362021A2 CO11058574A CO11058574A CO6362021A2 CO 6362021 A2 CO6362021 A2 CO 6362021A2 CO 11058574 A CO11058574 A CO 11058574A CO 11058574 A CO11058574 A CO 11058574A CO 6362021 A2 CO6362021 A2 CO 6362021A2
Authority
CO
Colombia
Prior art keywords
variants
compositions
methods
patient
soluble thrombomodulin
Prior art date
Application number
CO11058574A
Other languages
English (en)
Inventor
David Thompson Berg
Brian William Grinnell
Akanksha Gupta
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6362021A2 publication Critical patent/CO6362021A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención provee un método para prevenir y/o tratar un paciente con una lesión renal aguda causada por una variedad de condiciones. El método comprende la administración al paciente variantes de trombomodulina soluble que no se une a trombina. Junto con el estándar de cuidado, variantes de trombomodulina soluble que no se unen a trombina prevendrán o reducirán la lesión renal aguda y posterior morbilidad y mortalidad.
CO11058574A 2008-11-12 2011-05-12 Composiciones y metodos de uso para variantes de trombomodulina CO6362021A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11380108P 2008-11-12 2008-11-12

Publications (1)

Publication Number Publication Date
CO6362021A2 true CO6362021A2 (es) 2012-01-20

Family

ID=42111790

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11058574A CO6362021A2 (es) 2008-11-12 2011-05-12 Composiciones y metodos de uso para variantes de trombomodulina

Country Status (21)

Country Link
US (1) US20110207670A1 (es)
EP (1) EP2355839A2 (es)
JP (1) JP2012508742A (es)
KR (1) KR20110083665A (es)
CN (1) CN102216326A (es)
AU (1) AU2009314413A1 (es)
BR (1) BRPI0922033A2 (es)
CA (1) CA2743141A1 (es)
CL (1) CL2011001065A1 (es)
CO (1) CO6362021A2 (es)
CR (1) CR20110239A (es)
DO (1) DOP2011000133A (es)
EA (1) EA201170679A1 (es)
EC (1) ECSP11011049A (es)
IL (1) IL212209A0 (es)
MA (1) MA32775B1 (es)
MX (1) MX2011005005A (es)
SV (1) SV2011003904A (es)
TN (1) TN2011000206A1 (es)
WO (1) WO2010056472A2 (es)
ZA (1) ZA201103179B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014020183A1 (de) * 2012-08-03 2014-02-06 Ici Immunochemical Intelligence Gmbh In-vitro-assay zur diagnose von störungen der hämostase
WO2021126822A1 (en) * 2019-12-20 2021-06-24 Blue Blood Biotech Corp. Thrombomodulin functional domains for use in promoting osteoblast functions and bone healing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000325A1 (en) * 1990-06-27 1992-01-09 Mochida Pharmaceutical Co., Ltd. Anticoagulant polypeptides
CA2156255C (en) * 1993-12-17 2008-02-05 Yasuyuki Kunihiro Soluble thrombomodulin-containing composition
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5639625A (en) * 1994-09-26 1997-06-17 Oklahoma Medical Research Foundation Method for detecting antibodies to thrombomodulin in patients
EP1573005A2 (en) * 2002-12-02 2005-09-14 Biovec LLC Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
WO2004076635A2 (en) * 2003-02-25 2004-09-10 Biovec B.V. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
PL1948216T3 (pl) * 2005-10-13 2011-10-31 Lilly Co Eli Leczenie ostrej niewydolności nerek za pomocą rozpuszczalnej trombomoduliny
CA2665691A1 (en) * 2006-10-06 2008-04-17 Asahi Kasei Pharma Corporation Agent for therapy and/or improvement of disseminated intravascular coagulation
CA2671863C (en) * 2006-12-12 2015-07-21 Eli Lilly And Company Method of treating acute renal failure with thrombomodulin variants

Also Published As

Publication number Publication date
JP2012508742A (ja) 2012-04-12
TN2011000206A1 (en) 2012-12-17
ECSP11011049A (es) 2011-06-30
WO2010056472A3 (en) 2010-08-19
KR20110083665A (ko) 2011-07-20
EP2355839A2 (en) 2011-08-17
AU2009314413A1 (en) 2010-05-20
DOP2011000133A (es) 2011-06-30
CA2743141A1 (en) 2010-05-20
US20110207670A1 (en) 2011-08-25
CN102216326A (zh) 2011-10-12
IL212209A0 (en) 2011-06-30
BRPI0922033A2 (pt) 2015-12-15
SV2011003904A (es) 2011-07-06
MX2011005005A (es) 2011-05-25
EA201170679A1 (ru) 2012-04-30
CR20110239A (es) 2011-06-09
WO2010056472A2 (en) 2010-05-20
CL2011001065A1 (es) 2011-10-07
ZA201103179B (en) 2012-10-31
MA32775B1 (fr) 2011-11-01

Similar Documents

Publication Publication Date Title
CL2016002262A1 (es) Composiciones y métodos para modular la expresión de ttr y vhb
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
EA201690582A1 (ru) Модуляторы фактора в комплемента
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CL2008001498A1 (es) Uso de un anticuerpo contra el factor d en la prevencion o tratamiento de una condicion ocular asociada al complemento.
CL2011001254A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente a cd38 y al menos melfalan; y su uso para el tratamiento contra el cancer.
ES2616049T3 (es) Mejora de la función renal con composiciones que contienen quercetina
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
NI201900096A (es) Moduladores de la expresión de pcsk9
EA201201406A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
ECSP13013094A (es) Composiciones de limpieza de sal colina
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
DOP2013000236A (es) Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn)
ES2508165T3 (es) Lactoferrina y sustancia blanca
GT200900153A (es) Agentes para combatir parasitos en animales
EA201070448A1 (ru) Новые композиции на основе таксоидов
CL2012001159A1 (es) Composicion que comprende un inhibidor de alfa-1-proteinasa (api), y como minimo, un aminoacido; kit que comprende dicha composicion que se utiliza como una composicion farmaceutica adecuada para administracion intravenosa.
EA201071412A1 (ru) Дронедарон для предотвращения кардиоверсии
ECSP11011049A (es) Composiciones y métodos de uso para variantes de trombomodulina soluble
CO2020003134A2 (es) Moduladores de la expresión de enac
CL2008002005A1 (es) Composicion faramceutica solida, estable para administracion oral, que comprende una sal de vinflunina hidrosoluble y al menos un diluyente definido y un lubricante; uso para tratar el cancer.

Legal Events

Date Code Title Description
FA Application withdrawn